Introduction {#s2}
============

Colony-stimulating factor 1 (CSF-1; M-CSF) was originally defined by its ability to promote macrophage development from bone marrow precursors in vitro \>40 yr ago ([@bib93]). Mice with an inactivating mutation in the *Csf1* gene ("osteopetrotic" mice \[*Csf1*^op/op^\]) display severely reduced tissue macrophages, including osteoclasts, leading to osteopetrosis and other developmental defects ([@bib113]). Equally, most macrophages are absent in mice lacking the cognate receptor for CSF-1 (*Csf1r^−/−^* mice), highlighting the importance of CSF-1--mediated CSF-1R signaling for macrophage development ([@bib29]; [@bib32]). Yet, *Csf1r*^−/−^ mice have an overall more severe phenotype than mice lacking *Csf1*, leading to the proposed existence of an alternative ligand for CSF-1R ([@bib29]). In 2008, IL-34 was identified as the additional ligand ([@bib60]). In the past decade, many studies provided insight into IL-34 biology, but many questions remain unanswered, specifically in terms of its function. Here we review recent findings regarding IL-34, outline the impact of IL-34 on the development of the mononuclear phagocyte system, and discuss the current understanding of the role of IL-34 in pathology.

IL-34 and CSF-1 signaling through CSF-1R {#s3}
========================================

IL-34 is a secreted homodimeric glycoprotein highly conserved among vertebrates and more conserved than CSF-1 among mammalian and avian species ([@bib39]; [@bib60]). CSF-1, however, exists in three isoforms, which can be either secreted or membrane bound ([@bib30]; [@bib72]). The dimers of IL-34 are noncovalently linked, in contrast to the disulfide-linked CSF-1 homodimers ([@bib61]; [@bib65]; [@bib78]). Despite binding to the same receptor, IL-34 and CSF-1 do not share sequence homology, but their active regions are similar ([@bib61]; [@bib65]). In vitro studies suggested that the two ligands could even form heterodimers ([@bib86]), but whether this occurs in vivo and translates into biological activity remains unknown.

Both ligands bind to the same regions of the tyrosine kinase receptor CSF-1R, leading to phosphorylation and homodimerization of the receptor ([Fig. 1](#fig1){ref-type="fig"}). CSF-1 and IL-34 similarly support cell growth and survival of human monocytes and their differentiation into macrophages ([@bib7]; [@bib13]; [@bib23]; [@bib60]; [@bib112]). Yet, some differences in signal transduction and polarization of macrophages were found. IL-34--stimulated macrophages induced eotaxin-1, while CSF-1--mediated signaling led to higher levels of MCP-1 ([@bib23]). IL-34 also promoted increased secretion of IL-10 and CCL17 in macrophages in comparison with CSF-1--exposed macrophages ([@bib13]). Interestingly, the two ligands seem to induce different transcriptional profiles in vivo in microglia, the resident macrophages in the brain parenchyma ([@bib53]).

![**IL-34 can bind three different receptors.** In addition to CSF-1R (CD115), which is the main receptor for IL-34, PTP-ζ and syndecan-1 (CD138) have recently been identified as alternative receptors ([@bib74]; [@bib87]). IL-34--mediated receptor activation can induce several signaling pathways, including proliferation, survival, migration, polarization, and differentiation ([@bib5]; [@bib45]; [@bib56]; [@bib101]). Y, tyrosine; P, phosphorylation.](JEM_20190290_Fig1){#fig1}

On the other hand, an overlapping function of the two ligands was demonstrated in transgenic mice lacking *Csf1* (*Csf1*^op/op^) but expressing *Il34* under the control of the CSF-1 promoter. This rescued the developmental defects of *Csf1*^op/op^ mice, suggesting that IL-34 can take over the function of CSF-1 if it is expressed in a similar spatiotemporal manner ([@bib112]). In addition, osteoclast deficiency in *Csf1*^op/op^ mice was compensated over time by IL-34 in the spleen ([@bib71]), indicating a functional redundancy of IL-34 and CSF-1. Yet, in the absence of either IL-34 or CSF-1, no increase of the respective other ligand was observed, arguing against a compensatory impact ([@bib112]). Thus, future studies may reveal potential differences in downstream CSF-1R signaling pathways triggered by either IL-34 or CSF-1 or whether similar CSF-1R signal transduction is determined by the regional ligand availability and/or abundance. This might also provide insight into the reason for the evolution of two ligands signaling through the same receptor.

IL-34 receptors {#s4}
---------------

CSF-1R is the main receptor for IL-34. While it is virtually expressed by all macrophages, monocytes, myeloid precursors, and a subset of dendritic cells, some other nonhematopoietic cells were also suggested to express CSF-1R ([@bib92]). Among those were placental trophoblasts, renal proximal tubular epithelial cells (TECs), and colonic epithelial cells ([@bib50]; [@bib52]; [@bib92]) and some neurons ([@bib27]; [@bib63]; [@bib73]). However, other studies ([@bib32]; [@bib53]; [@bib89]) could not provide evidence that CSF-1R is indeed expressed outside of the mononuclear phagocyte lineage (reviewed in [@bib49]).

Recently, alternative receptors engaging with IL-34 have been proposed: the receptor-type protein-tyrosine phosphatase-ζ (PTP-ζ) and syndecan 1 (CD138; [Fig. 1](#fig1){ref-type="fig"}; [@bib74]; [@bib87]). Within the central nervous system (CNS), the chondroitin sulfate proteoglycan PTP-ζ is expressed on neural progenitors, neurons, and glial cells and was shown to be involved in various neural functions (e.g., proliferation, migration, differentiation, synaptogenesis, and myelination; [@bib56]). Whether IL-34 indeed contributes to PTP-ζ signaling in vivo and whether IL-34 has overlapping functions with other PTP-ζ ligands remains to be shown. Furthermore, albeit with low affinity, IL-34 can bind syndecan-1, a type I transmembrane heparin sulfate proteoglycan ([@bib87]). Syndecan-1 expression correlated with IL-34--induced CSF-1R activation in macrophages in vitro ([@bib87]). Whether syndecan-1 modulates CSF-1R activities in vivo remains unclear.

Tissue expression of IL-34 and CSF-1 {#s5}
------------------------------------

Both IL-34 and CSF-1 seem to be broadly expressed in a variety of tissues in the steady state. *CSF1* mRNA can be identified in humans and mice in the brain, spleen, mammary gland, testis, kidney, and small intestine and also in human lymph nodes, bone marrow, uterus, and ovary ([@bib24]; [@bib90]; [@bib94]; [@bib118]). In addition, *Csf1* seems to be expressed in the heart, fat, pancreas, liver, and lung ([@bib96]). At the protein level, CSF-1 was detected in the human heart and the murine lung ([@bib11]; [@bib48]).

The highest levels of IL-34 are found in the brain and the skin, where it is expressed by neurons and keratinocytes, respectively ([@bib44]; [@bib73]; [@bib104]). *Il34* is further expressed in various tissues, including human and mouse heart, lung, liver, kidney, and testes, and in human intestine, thymus, spleen, colon, prostate, and lymph nodes ([@bib60]; [@bib71]; [@bib96]; [@bib104], [@bib106]; [Fig. 2 A](#fig2){ref-type="fig"}). While most of these studies reported gene expression, IL-34 protein was described in the healthy murine lung and human skin, kidney, intestine, spleen, and brain ([@bib3]; [@bib11]; [@bib37]; [@bib44]; [@bib60]). We also found that IL-34 protein was detectable across various mouse tissues, with highest expression in brain, skin, and lymph nodes ([Fig. 2 B](#fig2){ref-type="fig"}), consistent with published mRNA data. In many organs, the cell types producing IL-34, its distribution pattern compared with CSF-1, and its role in the function of tissue-resident macrophages remain to be investigated.

![**Tissue expression of IL-34 in the steady state. (A)** Shown are tissues and cell types expressing IL-34 under physiological conditions ([@bib60]; [@bib96]). In the brain, IL-34 is produced by neurons, which control microglial homeostasis in adulthood ([@bib44]; [@bib73]; [@bib104]). The maintenance of retinal microglia in the inner plexiform layer depends on IL-34 produced by retinal ganglion cells ([@bib77]). Epidermal keratinocyte--derived IL-34 is critical for the development and maintenance of LC ([@bib44]; [@bib104]). In the testis, IL-34 is secreted by seminiferous tubule germ cells and in the kidney by proximal renal tubule cells ([@bib104]). Vascular endothelial cells in the spleen were also shown to produce IL-34 ([@bib71]). **(B)** Heatmap shows IL-34 concentration of various tissues from C57BL/6 mice quantified by ELISA (R&D Systems; *n* = 3). Background was assessed using tissue lysates from *Il34*-deficient mice. Color code is pg/µg total protein.](JEM_20190290_Fig2){#fig2}

The role of IL-34 for microglia and Langerhans cells (LCs) {#s6}
----------------------------------------------------------

Many tissue macrophages are derived from embryonic precursors and self-maintain throughout adulthood ([@bib41]). LCs, the resident mononuclear phagocytes of the epidermis, are mostly derived from fetal liver monocytes ([@bib47]). In contrast, primitive macrophages generated in the yolk sac during early embryonic development give rise to microglia ([@bib43]). Similarly to most other tissue macrophages, the genesis of these two populations also depends on CSF-1R signaling ([@bib42], [@bib43]; [@bib44]). However, while most tissue macrophages rely solely on CSF-1 for their development, CSF-1 appears to only partially contribute to the development of LCs ([@bib17]; [@bib29]). Indeed, LC differentiation and maintenance are mostly dependent on IL-34, which is produced in the developing epidermis from embryonic day 17.5 onward. Consistent with this expression pattern, *Il34*-deficient mice display a reduction of LC precursors and absence of adult LCs ([@bib44]; [@bib104], [@bib106]).

Within the brain, expression of CSF-1 and IL-34 is nonoverlapping and spatially distinct ([@bib53]; [@bib73]). During embryogenesis, IL-34 is restricted to the marginal zone and cortical plate, whereas CSF-1 is expressed within the subventricular zone and the ventricular area. In the neonatal cortex, CSF-1 is detected in layer VI, and IL-34 is detected in layers II--V ([@bib73]). Despite the presence of IL-34 in the developing brain, microglial development in mice is not dependent on IL-34 but requires CSF-1 ([@bib44]; [@bib53]). Yet, in zebrafish, a further role of IL-34 in the colonization of embryonic macrophages to the anterior head was demonstrated ([@bib114]).

In contrast to development, adult microglia are reduced in *Il34*-deficient mice in regions correlating with high IL-34 expression, indicating that their maintenance depends on IL-34 ([@bib44]; [@bib104]). IL-34 is mainly produced by neurons, at the highest levels in the cortex, the hippocampus, and the striatum ([@bib44]; [@bib53]; [@bib104]; [@bib112]). In comparison, CSF-1 is predominantly expressed by astrocytes in the cerebellum, and in mice lacking CSF-1, cerebellar microglia were decreased, while in other regions, only moderate or no reduction of microglia was detected ([@bib14]; [@bib43]; [@bib53]; [@bib111]).

In addition to neurons, IL-34 is expressed by ependymal cells lining the ventricular system and in the choroid plexus ([@bib73]; [@bib104]). Whether this influences the development or function of choroid plexus macrophages requires more studies. In the retina, IL-34 expression was detected in retinal ganglion cells, where it also controls the homeostasis of one subset of retinal microglia residing in the inner plexiform layer ([@bib77]). Altogether, while CSF-1 is critical for microglial development, a region-specific expression of IL-34 and CSF-1 regulates microglial homeostasis, phenotype, and transcriptional profile.

IL-34 expression and function in pathological conditions {#s7}
========================================================

The importance of IL-34 for LCs and microglia has been described, but relatively little is known about its role in pathology. Here, we summarize studies showing correlations of IL-34 expression in a variety of diseases and discuss its potential function.

IL-34 in CNS pathology {#s8}
----------------------

In neuron--microglia cocultures, treatment of microglia with IL-34 triggered the upregulation of TGF-β, insulin-degrading enzyme, and the antioxidant enzyme heme oxygenase 1 (HO-1), which limited the neurotoxic effects of oligomeric amyloid-β 1--42 ([@bib64]; [@bib69]). IL-34 administration to the CNS in vivo promoted microglial accumulation and improved cognitive function in the APP/PS1 mouse model of Alzheimer's disease ([@bib69]), indicating a neuroprotective role of IL-34 via regulation of microglial function. Similarly, administration of IL-34 or CSF-1 reduced microgliosis and neuronal loss after kainic acid--induced excitotoxicity, a model for neurodegeneration ([@bib63]; [@bib103]). Finally, beneficial effects of IL-34 on neuropathology could also be shown in an animal model of prion disease where *Il34* deficiency led to accelerated PrP^Sc^ deposition and shorter survival ([@bib123]). Yet, terminally ill animals showed similar microglia numbers, proposing that increased susceptibility of *Il34*-deficient animals might be due to the decreased microglia numbers in steady state or altered functions in the absence of IL-34.

CSF-1R mutations are associated with neurodegenerative diseases, including adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, a hereditary diffuse white matter disorder ([@bib81]; [@bib82]). The underlying cause is the partial loss of CSF-1R signaling on microglia leading to microglial dysfunction. Whether decreased IL-34 or CSF-1--mediated CSF-1R transduction leads to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia pathogenesis and whether mutations affecting either ligand would lead to a similar disorder remain to be shown.

IL-34 in rheumatoid arthritis (RA) {#s9}
----------------------------------

RA is a complex autoimmune disease characterized by synovial inflammation and hyperplasia, bone and cartilage destruction, and systemic disorders affecting different organs ([@bib66]). Many studies revealed an association between RA severity and IL-34 expression. Higher serum levels of IL-34 in RA patients correlated with a variety of RA features and were described as an independent risk factor for radiographic progression in RA ([@bib70]; [@bib98]; [@bib19]; [@bib120]; [@bib117]; [@bib109]). Similarly, higher levels of IL-34 in the synovial fluid in RA patients were indicative of increased inflammation in the synovium ([@bib20]; [@bib51]; [@bib70]; [@bib98]; [@bib117]) and corresponded to higher histological severity of synovitis, increased hyperplasia, higher leukocyte counts, and increased levels of IL-6 and receptor activator of NF-κB ligand ([@bib20]; [@bib70]; [@bib108]). Synovial biopsies from RA patients showed that IL-34 is mostly expressed by fibroblast-like synovial cells (FLS) and endothelial cells ([@bib19]; [@bib20]; [@bib51]). Moreover, IL-34 production in FLS from RA patients was increased by the proinflammatory cytokines TNF-α and IL-1β and was inhibited by TGF-β1 and BMP-2 ([@bib20]; [@bib51]; [@bib108]). In comparison, while CSF-1 is also highly expressed by RA FLS, it is not enhanced upon TNF-α stimulation, indicating that the expression of the two cytokines is regulated by different mechanisms ([@bib51]). Consequently, serum levels of IL-34 could be used to predict the response to TNF-α antagonist therapy ([@bib31]; [@bib98]; [@bib120]). In line with these observations, injection of recombinant IL-34 in mice aggravated the disease severity of collagen-induced arthritis and promoted an increase in IL-6 and TNF-α ([@bib121]). Similarly, administration of CSF-1 exacerbated disease in models of arthritis ([@bib12]; [@bib15]). On the other hand, blocking CSF-1R in mice had a protective role in collagen-induced arthritis and was more effective than a TNF-α antagonist ([@bib40]). Nevertheless, it is not clear whether this effect was mediated only by neutralization of CSF-1R signaling or by the general depletion of macrophages upon CSF-1R blockade ([@bib84]). Altogether, IL-34 is induced by proinflammatory cytokines to sustain an inflammatory cascade promoting joint pathology. Future studies should further elucidate the precise mechanisms of IL-34 action in vivo and establish its possible role as a diagnostic or therapeutic factor.

IL-34 in systemic lupus erythematosus (SLE) and kidney disease {#s10}
--------------------------------------------------------------

SLE is a chronic autoimmune disease affecting different organs ([@bib99]). Increased serum levels of IL-34 in SLE patients correlated positively with SLE disease activity index, titers of anti--double-stranded DNA antibodies, and C-reactive protein and negatively with levels of C3 in serum ([@bib107]; [@bib116]). IL-34 was also found to be an independent risk factor for the development of lupus nephritis, an SLE-caused kidney inflammation with high morbidity and mortality ([@bib2]; [@bib22]). Both IL-34 and CSF-1 are expressed in TECs of the kidney in both SLE patients and the MRL-Fas^lpr^ mouse model of lupus nephritis. *Il34*-deficient MRL-Fas^lpr^ mice showed decreased kidney pathology, reduced signs of multiorgan failure, decreased infiltration of monocytes and lymphocytes in the kidney, and lower intrarenal production of chemokines and proinflammatory cytokines. Thus, IL-34 appears to promote lupus nephritis pathogenesis by supporting the accumulation of macrophages in the kidney ([@bib102]).

IL-34 and CSF-1 expression in TECs was also increased in another model of kidney pathology: ischemia--reperfusion acute kidney injury that can progress to chronic kidney disease ([@bib3]). Similarly to lupus nephritis, IL-34 promoted kidney pathology and TEC destruction, as well as proliferation of kidney macrophages and myeloid cell infiltration. IL-34 deficiency resulted in significant reduction in kidney atrophy and myeloid cell accumulation ([@bib3]). Overall, inflammation-induced IL-34 in the kidney promotes expansion and recruitment of myeloid cells to drive kidney destruction. Interestingly, CSF-1 was suggested to promote repair in models of acute kidney injury ([@bib1]; [@bib67]; [@bib119]), indicating opposing roles for CSF-1 and IL-34. How these two CSF-1R ligands can mediate opposing functions, however, remains to be defined.

IL-34 in other inflammatory diseases {#s11}
------------------------------------

*Il34* mRNA was up-regulated in the salivary glands of patients with Sjögren's syndrome, a chronic autoimmune disorder of the exocrine glands ([@bib25]; [@bib36]). IL-34 correlated with the expression of proinflammatory cytokines TNF-α, IL-1β, IL-17, and IL-23p19 and with infiltration of inflammatory monocytes ([@bib25]). In patients with Crohn's disease or ulcerative colitis, the two major forms of inflammatory bowel disease, IL-34 (and also CSF-1) was up-regulated in the inflamed colon epithelium through TNF-α--induced NF-κB signaling ([@bib37]; [@bib126]).

In nonalcoholic fatty liver disease, levels of CSF-1 and IL-34 were highly increased in the liver and the serum of patients with nonalcoholic fatty liver disease. IL-34 concentration increased with fibrosis progression and could be used as an independent diagnostic marker for fibrosis ([@bib91]). Likewise, IL-34 was expressed by hepatocytes in liver fibrosis induced by hepatitis B or C infection and also correlated with increasing liver fibrosis ([@bib80]; [@bib110]). Consistent with these findings in the clinic, in vitro IL-34--differentiated monocytes up-regulated profibrotic factors and promoted collagen I production in hepatic stellate cells, supporting a pathogenic function for IL-34 in promoting fibrotic liver diseases ([@bib80]).

Altogether, increased levels of IL-34 correlate with many inflammatory, autoimmune, metabolic, and cardiovascular disorders ([@bib18]; [@bib35]; [@bib58]; [@bib97]; [@bib115]; [@bib125]). Yet, clear evidence for a function of IL-34 in many of these disorders is lacking.

IL-34 in skin inflammation {#s12}
--------------------------

In contrast to the inflammatory diseases described above, acute skin inflammation (induced by UV light or in a mouse model of atopic dermatitis) results in down-regulation of IL-34 and increased expression of CSF-1 in the epidermis. This leads to a partial repopulation of LCs in *Il34*-deficient mice, suggesting that in inflammation, CSF-1 can replace IL-34 in supporting LC differentiation ([@bib42]; [@bib44]; [@bib104], [@bib106]). Consistent with the findings in animal models, in patients with atopic dermatitis, IL-34 expression was reduced compared with skin from healthy volunteers ([@bib33]). Thus, in the skin, IL-34 appears to be a homeostatic cytokine, which is down-regulated in acute inflammation. Experimental systems designed to elevate local levels of IL-34 in skin could limit skin inflammation and thus result in clinical benefit.

IL-34 in cancer {#s13}
---------------

Tumor-associated macrophages (TAMs) are implicated in tumor growth, metastasis formation, angiogenesis, and immune suppression/activation. Expression of CSF-1R as well as CSF-1 often correlates with poor prognosis in various types of cancer ([@bib10]; [@bib34]; [@bib54]; [@bib62]; [@bib83]; [@bib85]). Thus, the CSF-1R axis, which is involved in regulating the function of TAMs, represents an attractive target for immunotherapeutic strategies, and several approaches inhibiting CSF-1R are currently under clinical development ([@bib16]; [@bib55]; [@bib79]).

Regarding IL-34, emerging data also demonstrate its correlation with poor prognosis in several cancers, such as osteosarcoma and lung and breast cancer ([Fig. 3](#fig3){ref-type="fig"}; [@bib6]; [@bib105]). Expressed by various types of cancer cells and further induced upon chemotherapy treatment ([@bib4]; [@bib8]; [@bib26]; [@bib38]; [@bib105]), IL-34 binds to CSF-1R on mononuclear phagocytes, which play distinct roles during different stages of tumor progression ([@bib8]; [@bib76]; [@bib88]; [@bib124]). IL-34 contributes to new vessel formation and promotes tumor progression and metastasis via accumulation of TAMs ([@bib88]), as was shown for CSF-1 ([@bib28]; [@bib59]). Embryonic stem cell--derived IL-34 was shown to polarize bone marrow--derived macrophages into macrophages that phenotypically and functionally resemble TAMs, showing increased levels of Arg-1, Tie-2, and TNF-α, and which contributed to angiogenesis and teratoma progression ([@bib21]).

![**Protective and disease-promoting roles of IL-34 in disease.** High expression of IL-34 correlates with disease severity in autoimmune diseases (Sjögren's syndrome \[[@bib25]; [@bib36]\], SLE \[[@bib107]; [@bib116]\], psoriasis \[[@bib69]\], and RA \[[@bib19]; [@bib70]; [@bib98]; [@bib108]; [@bib117]; [@bib120]\]), inflammatory diseases (liver fibrosis \[[@bib91]; [@bib80]; [@bib110]\], kidney disease \[[@bib3]\], and inflammatory bowel disease \[[@bib37]; [@bib126]\]), cardiovascular disease (heart failure; [@bib35]; [@bib58]; [@bib97]; [@bib115]), metabolic diseases (diabetes \[[@bib18]; [@bib125]\] and obesity \[[@bib18]; [@bib125]\]), and cancer (osteosarcoma \[[@bib88]\], lung cancer \[[@bib6]\], and breast cancer \[[@bib105]\]). In contrast, IL-34 plays a protective role in some diseases, such as atopic dermatitis ([@bib33]), Alzheimer's disease ([@bib69]), and cancer (non--small cell lung cancer \[[@bib57]\], colorectal cancer \[[@bib105]\], breast cancer \[[@bib68]; [@bib100]\], lung cancer \[[@bib105]\], hematologic malignancies \[[@bib105]\], and head and neck cancer \[[@bib68]; [@bib100]\]).](JEM_20190290_Fig3){#fig3}

Another study showed that IL-34 produced by hepatocellular carcinoma cells increased TGF-α production by TAMs, which in turn inhibited the negative regulator of IL-34, miR-28-5p. This feedback loop was suggested to modulate hepatocellular carcinoma growth and metastasis and to promote tumor progression. Moreover, patients with low miR-28-5p expression, high IL-34 levels, and high numbers of TAMs had a poor prognosis with shorter overall survival ([@bib122]).

A potential involvement of IL-34 in immunotherapy resistance was demonstrated in a patient with metastatic melanoma. Resistance to anti--programmed cell death protein 1 immunotherapy was acquired concomitant with enhanced expression of IL-34 and increased frequencies of CD163^+^ macrophages ([@bib46]). A similar observation was made for CSF-1 ([@bib75]). Altogether, while a direct role of IL-34 on TAMs and in tumor progression and immunotherapy resistance still has to be demonstrated, it is a promising potential candidate for novel therapeutic strategies.

Yet, both IL-34 and CSF-1 were also shown to negatively correlate with tumor progression. CSF-1R blockade or anti--CSF-1 treatment promoted metastasis formation in several animal models ([@bib9]; [@bib95]). Likewise, lower expression of IL-34 was found in a cohort of patients with non--small cell lung cancer and was related to poor survival ([@bib105]). In addition, high expression of IL-34 also seemed to be favorable in some cases of hematologic malignancies, head and neck cancer, and breast and colorectal cancers ([@bib68]; [@bib100]; [@bib105]). This suggests that the function of IL-34 in cancer may be multidimensional and can vary across different types of tumors and tissues.

Concluding remarks {#s14}
==================

IL-34 is a fairly new member of the family of "myelopoietic" cytokines. Originally described as a nonredundant growth factor specifically regulating LC development and microglial homeostasis, recent advances suggest that IL-34 is also expressed in a host of tissues other than skin and brain, in both the steady state and inflammation. However, whether IL-34 supports the generation, maintenance, or function of the resident macrophage compartment in these various organs requires further studies. In addition, the distribution pattern of IL-34 compared with CSF-1 in a given tissue might dictate the regulation of different macrophage subsets and their functions.

In pathological conditions, IL-34 seems to be involved in an array of diseases ranging from inflammation and autoimmunity to cancer. Nonetheless, while many human studies predominantly show a correlation between disease progression and IL-34 expression, very little is known about the actual function of IL-34. Additionally, whether IL-34 is beneficial or detrimental in a given pathology appears to be disease dependent, adding a layer of complexity to uncovering the biological roles of this cytokine. Thus, further research will reveal whether IL-34 indeed sustains an inflammatory disease, has proinflammatory or immunoregulatory properties, or is simply a hallmark of inflammation. This information will provide the necessary insight into whether IL-34 can serve as a predictive biomarker or even be exploited as a therapeutic target. Due to experimental design limitations, in many studies, including the ones discussed here, CSF-1 and IL-34 were not analyzed simultaneously. Thus, a further challenge is to carefully dissect similarities and differences between CSF-1 and IL-34 signaling and to identify the regulation and activities of both cytokines and their spatiotemporal expression pattern across tissues in pathological conditions. In cancer, for example, specific targeting of either CSF-1 or IL-34 instead of CSF-1R blockage, which eliminates most tissue macrophages, could be advantageous and could offer new perspectives for therapeutic interventions. Recent technologies (such as mass cytometry, multiparameter flow cytometric analysis, and single-cell RNA sequencing) combined with animal models and conditional mutagenesis should further help to advance our understanding of the interplay between IL-34, macrophages, and the immune system and could point toward novel disease mechanisms.
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